A group of experts discuss implications for patient access in CLL.
Video content above is prompted by the following question(s):
Liso-Cel Prolongs Responses, PFS, and OS in Pretreated, High-Risk R/R CLL
March 7th 2025Treatment with liso-cel induced long-term complete remission rates and high undetectable minimal residual disease rates in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma following progression on Bruton tyrosine kinase inhibition and venetoclax.
Read More
Ibrutinib Benefits R/R CLL, but Combo Therapy Works Better
March 5th 2025Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it with other therapies can improve response rates and may allow for treatment discontinuation in some patients.
Read More
Personalized CLL Therapy With MRD Guidance Improves Survival Outcomes
February 6th 2025A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with standard chemoimmunotherapy.
Read More